141 related articles for article (PubMed ID: 31866083)
1. The influence of hormone replacement therapy on lung cancer incidence and mortality.
Titan AL; He H; Lui N; Liou D; Berry M; Shrager JB; Backhus LM
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1546-1556.e4. PubMed ID: 31866083
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis.
Abdel-Rahman O
Int J Clin Oncol; 2020 May; 25(5):885-891. PubMed ID: 31919692
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy and lung cancer risk: a case-control analysis.
Schabath MB; Wu X; Vassilopoulou-Sellin R; Vaporciyan AA; Spitz MR
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):113-23. PubMed ID: 14734459
[TBL] [Abstract][Full Text] [Related]
4. Hormone Replacement Therapy and Colorectal Cancer Incidence and Mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Symer MM; Wong NZ; Abelson JS; Milsom JW; Yeo HL
Clin Colorectal Cancer; 2018 Jun; 17(2):e281-e288. PubMed ID: 29398422
[TBL] [Abstract][Full Text] [Related]
5. Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy?
Olsson H; Bladström A; Ingvar C
Obstet Gynecol; 2003 Sep; 102(3):565-70. PubMed ID: 12962944
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and survival in non-small cell lung cancer patients by smoking history: a population-based cohort study.
Löfling L; Karimi A; Sandin F; Bahmanyar S; Kieler H; Lambe M; Lamberg K; Wagenius G
Acta Oncol; 2019 Nov; 58(11):1618-1627. PubMed ID: 31373239
[No Abstract] [Full Text] [Related]
7. Association of hormone replacement therapy with mortality in colorectal cancer survivor: a systematic review and meta-analysis.
Jang YC; Huang HL; Leung CY
BMC Cancer; 2019 Dec; 19(1):1199. PubMed ID: 31818262
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
Darling GE; Li F; Patsios D; Massey C; Wallis AG; Coate L; Keshavjee S; Pierre A; De Perrot M; Yasufuku K; Cypel M; Waddell T
Eur J Cardiothorac Surg; 2015 Nov; 48(5):684-90; discussion 690. PubMed ID: 25567960
[TBL] [Abstract][Full Text] [Related]
9. Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer.
Shin JY; Yoon JK; Marwaha G
Lung; 2018 Jun; 196(3):351-358. PubMed ID: 29550987
[TBL] [Abstract][Full Text] [Related]
10. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.
Schuetz F; Diel IJ; Pueschel M; von Holst T; Solomayer EF; Lange S; Sinn P; Bastert G; Sohn C
Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414
[TBL] [Abstract][Full Text] [Related]
11. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer.
Bryant A; Cerfolio RJ
Chest; 2007 Jul; 132(1):185-92. PubMed ID: 17573517
[TBL] [Abstract][Full Text] [Related]
12. Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC).
Subramanian J; Velcheti V; Gao F; Govindan R
J Thorac Oncol; 2007 Sep; 2(9):827-30. PubMed ID: 17805060
[TBL] [Abstract][Full Text] [Related]
13. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women.
Schwartz AG; Wenzlaff AS; Prysak GM; Murphy V; Cote ML; Brooks SC; Skafar DF; Lonardo F
J Clin Oncol; 2007 Dec; 25(36):5785-92. PubMed ID: 18089876
[TBL] [Abstract][Full Text] [Related]
14. Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer.
Moore KA; Mery CM; Jaklitsch MT; Estocin AP; Bueno R; Swanson SJ; Sugarbaker DJ; Lukanich JM
Ann Thorac Surg; 2003 Dec; 76(6):1789-95. PubMed ID: 14667585
[TBL] [Abstract][Full Text] [Related]
15. Treatment of clinical T4 stage superior sulcus non-small cell lung cancer: a propensity-matched analysis of the surveillance, epidemiology, and end results database.
Wen J; Liu D; Chen D; Chen J; Xu X; Chen C; Zhang F; Duan S; Zhu R; Fan M; Chen Y
Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30647107
[No Abstract] [Full Text] [Related]
16. Oral contraceptives, hormone replacement therapy and breast cancer risk: a cohort study of 16 928 women 48 years and older.
Thorbjarnardottir T; Olafsdottir EJ; Valdimarsdottir UA; Olafsson O; Tryggvadottir L
Acta Oncol; 2014 Jun; 53(6):752-8. PubMed ID: 24460068
[TBL] [Abstract][Full Text] [Related]
17. Estimation of the tumor size at cure threshold among aggressive non-small cell lung cancers (NSCLCs): evidence from the surveillance, epidemiology, and end results (SEER) program and the national lung screening trial (NLST).
Goldwasser DL
Int J Cancer; 2017 Mar; 140(6):1280-1292. PubMed ID: 27925181
[TBL] [Abstract][Full Text] [Related]
18. Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer--a population based cohort study, the HUNT study: are proxy variables friends or faults?
Hatlen P; Langhammer A; Forsmo S; Carlsen SM; Amundsen T
Lung Cancer; 2013 Jul; 81(1):39-46. PubMed ID: 23618654
[TBL] [Abstract][Full Text] [Related]
19. Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.
Deepak JA; Ng X; Feliciano J; Mao L; Davidoff AJ
Ann Am Thorac Soc; 2015 May; 12(5):742-51. PubMed ID: 25760983
[TBL] [Abstract][Full Text] [Related]
20. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study.
Feigelson HS; Jonas CR; Teras LR; Thun MJ; Calle EE
Cancer Epidemiol Biomarkers Prev; 2004 Feb; 13(2):220-4. PubMed ID: 14973094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
